Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 106 clinical trials
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferetive neoplasms. TGFβ signaling is known to be abnormally high in patients with myeloproliferative neoplasms and it is thought that abnormal TGFβ signals cause many of the problems with blood cell formation …

ruxolitinib
hydroxyurea
myelodysplastic/myeloproliferative neoplasm
anemia
  • 0 views
  • 21 Feb, 2022
  • 1 location
Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy

EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the most effective treatment remains unknown. This study is trying to evaluate the efficacy and safety of PD-1 monoclonal antibody as a first-line therapy …

  • 2 views
  • 15 Sep, 2021
  • 1 location
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Background Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of …

bone marrow procedure
granulocyte colony stimulating factor
busulfan
oxygen saturation
hla typing
  • 15 views
  • 28 Jun, 2022
  • 2 locations
Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc) patients

  • 8 views
  • 26 Mar, 2021
  • 1 location
Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease (SCLEROJAKI)

sclerosis demonstrated the efficacy of ruxolitinib and tofacitinib on cutaneous and pulmonary fibrosis. Recently, tofacitinib was evaluated in SSc patients in two clinical studies and showed significant

fibrosis
pulmonary fibrosis
interstitial lung disease
progressive systemic sclerosis
arthritis
  • 0 views
  • 26 Mar, 2022
  • 1 location
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis (ALLO-BAT)

The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis. This will be done by asking participants to choose the treatment that they prefer to receive (HCT or BAT) and …

hydroxyurea
essential thrombocythemia
cancer
polycythemia
ruxolitinib
  • 0 views
  • 13 Jun, 2022
  • 2 locations